Clinical Trials Browser

Phase 2 × Has results × ceritinib × Clear all

NCT03737994 2026-03-18

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Active not recruiting

10 enrolled 17 charts

Lung Neoplasms

NCT02513667 2023-02-03

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

Phase 2 Terminated

14 enrolled 12 charts

ALK-positive Non-small Cell Lung Cancer

NCT02186821 2021-04-08

SIGNATURE

Phase 2 Terminated

47 enrolled 13 charts

LymphoidOther hematologic neoplasm

Lymphoma, B-Cell, Hematologic Neoplasms

NCT02450903 2021-03-30

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Phase 2 Completed

20 enrolled 12 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02336451 2020-04-21

Ascend-7

Phase 2 Completed

156 enrolled 39 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Phase 2 Terminated

1 enrolled 7 charts

Noonan Syndrome 6, Melanoma

NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Phase 2 Terminated

22 enrolled 16 charts

CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

NCT01685138 2019-03-26

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Phase 2 Completed

124 enrolled 18 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01685060 2017-06-19

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Phase 2 Completed

140 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung